The Revisited Classification of GN in SLE at 10 Years

Wilhelmus, Suzanne; Alpers, Charles E.; Cook, H. Terence; Ferrario, Franco; Fogo, Agnes B.; Haas, Mark; Joh, Kensuke; Nôël, Laure-Hélène; Seshan, Surya V.; Bruijn, Jan A.; Bajema, Ingeborg M.

doi:10.1681/asn.2015040384

Cited by 57 publications

(69 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mesangial cell proliferation is among the primary lesion characteristics of LN (27), and the immunofluorescence results suggested that cell proliferation was increased in the biopsied tissue of patients with LN (Fig. 1C).…”

Section: Effect Of Tweak On Nf-κb Transcriptional Activity Hmc Prolimentioning

confidence: 94%

Involvement of TWEAK and the NF-κB signaling pathway in lupus nephritis

Sun

Teng

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Previous findings have identified that tumor necrosis factor-related weak inducer of apoptosis (TWEAK) is associated with lupus nephritis (LN) activity status; however, the mechanism involved remains unclear. The present study aimed to investigate the roles of TWEAK and the nuclear factor (NF)-κB signaling pathway in LN. TWEAK levels in the blood and urine of patients with LN or non-LN systemic lupus erythematosus were measured by ELISA and compared with those in healthy controls. TWEAK expression and NF-κB transcriptional activity in the kidney were detected by western blotting, and Ki-67 and cluster of differentiation (CD) 68 expression were assessed using immunofluorescence. Additionally, human mesangial cells (HMCs) were cultured in vitro and divided into five groups: Normal control, TWEAK stimulus group, TWEAK + TWEAK blocking antibody, TWEAK + NF-κB inhibitor (BAY 11-7082) and TWEAK + combined (blocking antibody + BAY 11-7082). Cell cycle activity and Ki-67 expression in the HMCs were evaluated using flow cytometry, and cell induction of macrophage chemotaxis was determined by a Transwell assay. Levels of the inflammation-associated factors interleukin (IL)-6, monocyte chemotactic protein 1 (MCP-1), chemokine ligand 5 (CCL5), IL-8 and IL-10 were also detected by reverse transcription-quantitative polymerase chain reaction. It was observed that the urine levels of TWEAK in patients with LN were significantly elevated compared with those in the other groups (P<0.05). LN kidneys exhibited markedly increased cell proliferative ability, macrophage infiltration, TWEAK expression and NF-κB transcriptional activity compared with normal kidneys. Furthermore, the results indicated that treatment with recombinant TWEAK notably enhanced NF-κB transcriptional activity and significantly promoted cell proliferation and cell cycle activity (P<0.05), induced macrophage chemotaxis (P<0.05), significantly increased the expression of the chemotactic factors IL-6, IL-8, MCP-1 and CCL5 (P<0.05), and significantly reduced anti-inflammatory cytokine IL-10 mRNA expression in HMCs (P<0.05), relative to normal controls. Accordingly, blocking TWEAK function or inhibiting NF-κB activity reversed these effects. Collectively these data indicate that urine TWEAK may be considered as a novel biomarker of LN activity, and that blocking TWEAK function or NF-κB activity may effectively alleviate glomerular mesangial cell proliferation and macrophage chemotaxis.

show abstract

Section: Effect Of Tweak On Nf-κb Transcriptional Activity Hmc Prolimentioning

confidence: 94%

Involvement of TWEAK and the NF-κB signaling pathway in lupus nephritis

Sun

Teng

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…In comparison with the older classifications [3,4,18], the ISN/ RPS classification allows a more detailed definition of the different classes with better reproducibility of the results among pathologists [19]. However, there are some points that need to be clarified such as the definition of endocapillary and extracapillary proliferation, a number of glomerular lesions not included in the classification, the value of activity and chronicity index, and the importance of tubulo-interstitial and vascular lesions [20].…”

Section: Introduction To Lupus Nephritismentioning

confidence: 99%

Lupus nephritis: When and how often to biopsy and what does it mean?

Moroni

Depetri

Ponticelli

2016

Journal of Autoimmunity

View full text Add to dashboard Cite

“…At present, data supporting an association between MCD and FSGS with SLE are limited to the observation that these entities seem to be more common in SLE and are often present in the setting of a lupus flare; a goal for the future will be to connect these entities in more than an observational manner. Another important question is whether lupus podocytopathy will be added to the next revision of the classification of LN (7). For now, and in significant part because of the contribution of the work by Hu et al (5), we have reached the point that lupus podocytopathy should be considered a distinct and recognizable disease entity.…”

mentioning

confidence: 99%